Bourla said he had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid, and was isolating and following all public health precautions.
Paxlovid is an antiviral medication that is used to treat high-risk patients, such as older people.
Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Subscribe to The Economic Times Prime and read the ET ePaper online.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Subscribe to The Economic Times Prime and read the ET ePaper online.